Multifunctional Nanoparticles for Magnetic Hyperthermia and Indirect Radiation Therapy (RADIOMAG)

The aim of this COST Action is to bring together and organise the research outcomes from the different participating network members in a practical way to provide clinicians with the necessary input to trial a novel anti-cancer treatment combining magnetic hyperthermia (MH) and radiotherapy, also identifying future research objectives upon appraisal of the obtained results. Feedback between the different working groups here is essential, and is expected that the lifetime of this Action proposal will eventually result in a compendium of best practices for magnetic hyperthermia.

RADIOMAG will generate new and strengthen the existing synergies between technical advances (thermal imaging / MH), new treatment concepts (combined targeting radiosensitisation and magnetic thermotherapy) and biocompatible coating in order to achieve a breakthrough in the clinical application of magnetic hyperthermia. Due to the complexity of this aim, synergies can only be achieved on a longer time frame, by means of workshops, short-term scientific missions, joint publications, common Horizon 2020 research proposals and exchange with other COST Actions.

The network consists of 180 members from 30 countries. Its related activities are funded by the European Cooperation in Science and Technology (COST), and the grant is administrated by the Royal Meteorological Institute of Belgium.

Funding: EU COST Action TD1402  (2014 - 2018)